Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination.

BACKGROUND Response to challenge with live, attenuated, oral polio vaccine (OPV) is a measure of immunity induced by prior immunization. METHODS Using stool samples from a study from Oman in which an initial schedule of inactivated polio vaccine (IPV) was followed by an OPV type 1 challenge, we quantitated virus shed, sequenced capsid proteins of recovered virus, and developed assays for neutralization of poliovirus and mucosal immunoglobulin A (IgA) detection. RESULTS Neutralizing activity correlated with detection of polio-specific IgA in stool suspensions collected 7 days after OPV type 1 challenge. Both neutralization and IgA in stool were associated with cessation of virus shedding by day 7. Rapid development of an IgA response with cessation of shedding suggests that IPV primed for the early response to challenge. Correlation of neutralization activity and IgA detection provides evidence that polio-specific IgA intestinal antibody is a determinant of mucosal shedding/transmission and that IgA functions through neutralization of virus. In contrast, neither presence nor quantity of serum or intestinal antibody induced by IPV prior to challenge correlated with cessation of shedding. CONCLUSIONS These assays provide an opportunity to study other immunization schedules to gain a broader understanding of the appearance and duration of a protective mucosal response to polio vaccination.

[1]  M. Pallansch,et al.  Expert Review on Poliovirus Immunity and Transmission , 2013, Risk analysis : an official publication of the Society for Risk Analysis.

[2]  R. Sutter,et al.  Priming after a fractional dose of inactivated poliovirus vaccine. , 2013, The New England journal of medicine.

[3]  C. Bailey-Kellogg,et al.  High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. , 2012, Journal of immunological methods.

[4]  N. Grassly,et al.  Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge , 2012, PLoS pathogens.

[5]  T. Wakita,et al.  Development of a Poliovirus Neutralization Test with Poliovirus Pseudovirus for Measurement of Neutralizing Antibody Titer in Human Serum , 2011, Clinical and Vaccine Immunology.

[6]  M. Pallansch,et al.  Fractional doses of inactivated poliovirus vaccine in Oman. , 2010, The New England journal of medicine.

[7]  N. Grassly,et al.  Asymptomatic wild-type poliovirus infection in India among children with previous oral poliovirus vaccination. , 2010, The Journal of infectious diseases.

[8]  J. van de Kassteele,et al.  Shedding of Vaccine Viruses with Increased Antigenic and Genetic Divergence after Vaccination of Newborns with Monovalent Type 1 Oral Poliovirus Vaccine , 2009, Journal of Virology.

[9]  Miguel A. Galindo,et al.  Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba , 2007 .

[10]  N. Nagata,et al.  Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. , 2006, The Journal of general virology.

[11]  G. Dunn,et al.  Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains , 2005, Journal of medical virology.

[12]  T. Kimman,et al.  Immunoglobulin a as a serological marker for the (silent) circulation of poliovirus in an inactivated poliovirus-vaccinated population. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Y. Manor,et al.  Detection of Poliovirus Circulation by Environmental Surveillance in the Absence of Clinical Cases in Israel and the Palestinian Authority , 1999, Journal of Clinical Microbiology.

[14]  C. Meschievitz,et al.  Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. , 1997, The Journal of infectious diseases.

[15]  Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. , 1997, The Journal of infectious diseases.

[16]  P. Wright,et al.  Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. , 1995, The Pediatric infectious disease journal.

[17]  J. Modlin,et al.  Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. , 1993, The Journal of infectious diseases.

[18]  M. Böttiger The elimination of polio in the Scandinavian countries. , 1993, Public health reviews.

[19]  P. Wright,et al.  Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. , 1991, Reviews of infectious diseases.

[20]  I. Onorato,et al.  Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. , 1991, The Journal of infectious diseases.

[21]  P. Wright,et al.  Candidate rotavirus vaccine (rhesus rotavirus strain) in children: an evaluation. , 1987, Pediatrics.

[22]  K. Mcintosh,et al.  Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection , 1979, Infection and immunity.

[23]  P. Ogra,et al.  Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. , 1968, The New England journal of medicine.

[24]  R. Couch,et al.  Homologous and heterologous resistance to rhinovirus common cold. , 1965, American journal of epidemiology.

[25]  D. Bodian Emerging concept of poliomyelitis infection. , 1955, Science.